Rila Therapeutics

Rila Therapeutics is a biotechnology company with the slogan "Addressing the burden of chronic fibrotic disease." Founded in 2021, the company is focused on developing novel therapeutics to treat fibrotic diseases. It was co-founded by John He, the chief of nephrology at Icahn Mount Sinai and a key opinion leader at one of the largest medical centers in the U.S., as well as ShangPharma Innovation. John He, in addition to his position at Icahn Mount Sinai, is a professor of medicine and pharmacological sciences. He has made significant contributions to the understanding of kidney disease pathogenesis. His academic work has shed light on multiple features of kidney disease pathogenesis, leading to the elucidation of complex signaling networks in kidney cells by using systems biology approach and transgenic mouse models, and revealing the novel mechanisms of kidney fibrosis. Rila Therapeutics operates in the health care industry and is headquartered in the United States. The company recently received a Venture Round investment on 01 January 2022 from ShangPharma. In summary, Rila Therapeutics, led by prominent figures in the nephrology and biotechnology fields, is dedicated to addressing the challenges of fibrotic diseases through innovative therapeutic approaches, making it an intriguing prospect for venture capital investment.